All Q2 FY26 results →
MI

Mettler-Toledo International Inc.

Q2 FY26Life Sciences Tools and Services

Mettler-Toledo International Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹1,164
Market cap₹23.5K Cr
P/E25.9
Updated29 May 2026
Read4 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

- The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. - Full-year 2026 local currency sales growth: Approximately 4%, including about 1.5% contribution from acquisitions in H1 and less than 8% for full year.

From Mettler-Toledo International Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. (Page 3)
  • There is optimism for growth in the second half of 2026, supported by a stronger sales pipeline and improving customer activity despite caution in the first half due to geopolitical uncertainty and customer delays. (Pages 3, 13)
  • Growth in specific high-potential segments such as bioprocessing, semiconductor-related ultra-pure water, and industrial automation is expected to fuel future revenue expansion. (Pages 3, 12, 13)
  • China and emerging markets like India are showing good momentum and contributing to growth expectations. (Pages 3, 8, 13)

2 more points from Mettler-Toledo International Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Mettler-Toledo International Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company received a $6 million grant from the local government in Shanghai encouraging expansion of capacity, local manufacturing, and research (Page 13).
  • The grant includes CapEx-related and OpEx-related components, with CapEx part supporting capacity expansion (Page 13).
  • There is a focus on investments in innovations such as the R&D accelerator and JetStream programs to increase the pace of innovation, especially in high-growth segments like bioprocessing (Page 3).
  • The company is investing in automation and digitalization solutions to address growing demand in industrial and pharma markets (Pages 11 & 12).

Fundraising & Capital Structure

See what Mettler-Toledo International Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The company typically carries about 1.5 months of backlog, which limits visibility from orderbook length.
  • They track multiple KPIs across the sales funnel from opportunities to orders.
  • Recent reviews with executive teams and the Board suggest increased pipeline activity compared to earlier in the year.
  • Despite geopolitical uncertainties causing some customer delays, there have been no cancellations; delays appear as pushouts rather than losses.

2 more points from Mettler-Toledo International Inc.'s call on order book

Create a free account to keep reading this call

Others in Life Sciences Tools and Services this season

  • Revvity, Inc. (Q2 FY26)

    Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t

  • Medpace Holdings, Inc. (Q2 FY26)

    Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations

  • Illumina, Inc. (Q2 FY26)

    Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma

  • West Pharmaceutical Services, Inc. (Q2 FY26)

    West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Mettler-Toledo International Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Mettler-Toledo International Inc. Q2 FY26 results?

- The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. - Full-year 2026 local currency sales growth: Approximately 4%, including about 1.5% contribution from acquisitions in H1 and less than 8% for full year.

What is Mettler-Toledo International Inc. share price analysis?

Mettler-Toledo International Inc. currently shows a neutral. The stock trades at a P/E of 25.9 with a market cap of $23,512. Investors should review the full earnings analysis for detailed insights.

Is Mettler-Toledo International Inc. planning capital expenditure?

- The company received a $6 million grant from the local government in Shanghai encouraging expansion of capacity, local manufacturing, and research (Page 13).

Keep Mettler-Toledo International Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.